Breaking News, Financial News

Schott Full Year Revenues Up 7%

55% of revenue in FY 2024 came from strong-margin HVS.

Author Image

By: Charlie Sternberg

Associate Editor

Schott Pharma 4Q Revenues: $249 million (+4%) FY Revenues: $1 billion (+7%) Comments: The main driver of SCHOTT Pharma’s revenue growth in Q4 2024 was the strong year-end finish of the DDS segment. Revenues in the DDS segment reached $124 million, an increase of 12% yoy (at constant currencies: 11%). Q4 represented the highest quarterly revenue in this segment. This development was driven by the ongoing strong demand for prefillable syringes and, in particular, by good momentum in glass syrin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters